N. Burchardi

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

M. Rezai, P. Fasching, A. Schneeweiss, 2017 .

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.

S. Loibl, N. Burchardi, I. Ray-Coquard, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group.

S. Loibl, N. Burchardi, I. Vergote, 2011, Gynecologic oncology.

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).

H. Kölbl, S. Loibl, N. Burchardi, 2007, Gynecologic oncology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Abstract P1-13-05: GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses

A. Schneeweiss, S. Loibl, N. Burchardi, 2016 .

Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).

M. Rezai, P. Fasching, A. Schneeweiss, 2016, European journal of cancer.

Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First-Line Chemotherapy: A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany

N. Burchardi, J. Huober, P. Harter, 2009, International Journal of Gynecologic Cancer.

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry.

P. Fasching, T. Fehm, T. Park-Simon, 2018, European journal of cancer.

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Sung-Bae Kim, K. Gelmon, H. Rugo, 2022, Frontiers in Oncology.

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

C. Denkert, F. Marmé, S. Loibl, 2022, Breast.

Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry

T. Fehm, T. Park-Simon, S. Loibl, 2016, International journal of molecular sciences.

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

C. Denkert, W. Eiermann, F. Marmé, 2015, Cancer.

A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

C. Denkert, N. Burchardi, V. Nekljudova, 2022, ESMO open.

Physician Assisted Suicide: Knowledge and Views of Fifth-Year Medical Students in Germany

N. Burchardi, J. Schildmann, J. Vollmann, 2006, Death studies.

Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients

N. Burchardi, M. Beck, M. Hecht, 2005, Journal of the Neurological Sciences.

Teaching and evaluating breaking bad news: a pre-post evaluation study of a teaching intervention for medical students and a comparative analysis of different measurement instruments and raters.

N. Burchardi, J. Schildmann, J. Vollmann, 2012, Patient education and counseling.

Breaking bad news: evaluation study on self-perceived competences and views of medical and nursing students taking part in a collaborative workshop

N. Burchardi, J. Schildmann, J. Vollmann, 2006, Supportive Care in Cancer.

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of the Therapeutic Efficacy of a Fixed Low-Dose Combination of Cinnarizine and Dimenhydrinate with Betahistine in Vestibular Neuritis

N. Burchardi, W. Baumann, A. Scholtz, 2012, Clinical Drug Investigation.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy—an open-label, prospective, randomised controlled multicenter study

C. Schade-Brittinger, W. Oertel, H. Lerche, 2012, Journal of Neurology, Neurosurgery & Psychiatry.

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Clinical Cancer Research.

Abstract P4-08-26: Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

P. Fasching, T. Fehm, S. Loibl, 2019, Poster Session Abstracts.

Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70)

A. Schneeweiss, C. Denkert, S. Loibl, 2015, Clinical Cancer Research.

Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

S. Loibl, N. Burchardi, I. Vergote, 2007 .

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.

K. Weber, M. Rezai, P. Fasching, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jacqueline A. Hall, Sarah N. Dudgeon, A. Gown, 2020, npj Breast Cancer.

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

P. Fasching, A. Schneeweiss, C. Denkert, 2021, Journal of Clinical Oncology.

Quality of reporting of clinical non-inferiority and equivalence randomised trials - update and extension

Meinhard Kieser, Michael Niestroj, N. Burchardi, 2012, Trials.

[The "bad news consultation assessment scale" (Aufklärungsgesprächbewertungsskala, AGBS): a tool for assessing communication competencies when breaking bad news to cancer patients].

N. Burchardi, J. Schildmann, J. Vollmann, 2007, Zeitschrift fur arztliche Fortbildung und Qualitatssicherung.

Abstract P6-17-08: Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry

T. Fehm, T. Kühn, T. Park-Simon, 2016 .

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).

P. Fasching, A. Schneeweiss, C. Denkert, 2017, European journal of cancer.

264PDGAIN2: ADJUVANT PHASE III TRIAL COMPARING AN INTENSIFIED DOSE-DENSE ADJUVANT THERAPY WITH ENPC COMPARED WITH A DOSE-DENSE, DOSE-ADAPTED THERAPY WITH DTEC DTDOCETAXEL IN PATIENTS WITH PRIMARY BREAST CANCER AND A HIGH RISK OF RECURRENCE.

A. Schneeweiss, S. Loibl, N. Burchardi, 2014, Annals of Oncology.

Teaching and evaluating breaking bad news: a pre-post evaluation study of a teaching intervention for medical students and a comparative analysis of different measurement instruments and raters.

N. Burchardi, J. Schildmann, J. Vollmann, 2012, Patient education and counseling.

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).

A. Schneeweiss, C. Denkert, F. Marmé, 2021, European journal of cancer.

Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021 .

Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial

A. Schneeweiss, F. Marmé, S. Loibl, 2019, Poster Discussion Abstracts.